Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations – 42% of patients with AR ligand binding domain (LBD) mutations...
COGENT BIOSCIENCES ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING OF SHARES OF COMMON STOCK WALTHAM, Mass. and BOULDER, Colo., June 06, 2023 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision...
COGENT BIOSCIENCES ANNOUNCES POSITIVE LEAD-IN DATA FROM ONGOING PHASE 3 PEAK TRIAL EVALUATING BEZUCLASTINIB IN COMBINATION WITH SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS (GIST) – Data presented at ASCO annual meeting demonstrate 55% Disease...
Cleerly Partners with ProScan Imaging to Transform the Standard of Care for Heart Disease PreventionProScan’s imaging centers in two major regions will now leverage Cleerly’s AI-enabled approach to develop personalized heart care diagnoses and treatment plans DENVER –...
Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial NEW HAVEN, Conn. and SAN FRANCISCO, May 2, 2023 /PRNewswire/ — Arvinas, Inc. (Nasdaq: ARVN) and...
Rallybio Announces Clinical Proof-of-Concept Results for RLYB211, an Anti-HPA-1a Polyclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), Published in the Journal of Thrombosis and Haemostasis — Data Support Potential Use...
Recent Comments